To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
102 Current news of Pfizerrss
|You can refine your search further. Select from the filter options on the left to narrow down your results.|
Funding Supports Advancement of KAN-101 for Celiac Disease into Phase 2 Clinical Development
Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, announced that Pfizer has made a $35 million equity investment in Anokion through the Pfizer Breakthrough Growth Initiative. In conjunction with the investment, Michael ...
Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15
Valneva SE and Pfizer Inc. announced that they have entered into an Equity Subscription Agreement and have updated the terms of their Collaboration and License Agreement for Lyme disease vaccine candidate VLA15. As previously announced on April 26, 2022, Pfizer plans to initiate the Phase 3 study ...
The mRNA technology could to improve upon the efficacy of current flu vaccines
Pfizer Inc. announced that the first participants have been dosed in a Phase 1 clinical trial to evaluate the safety, tolerability, and immunogenicity of a single dose quadrivalent mRNA vaccine against influenza in healthy adults. Pfizer’s mRNA influenza vaccine program is the first in a planned ...
The U.S. Food and Drug Administration approved the first COVID-19 vaccine. The vaccine has been known as the Pfizer-BioNTech COVID-19 Vaccine, and will now be marketed as Comirnaty (koe-mir’-na-tee), for the prevention of COVID-19 disease in individuals 16 years of age and older. The vaccine also ...
“We are proud to work with Pfizer and to have their scientists use our software in their early discovery programs”
Iktos announced the application of Iktos Artificial Intelligence technology for de novo design to selected Pfizer small-molecule discovery programs. Over the last few years, phenomenal advances in AI algorithmic development and computational power have enabled innovative approaches in ...
Candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis
Pfizer Inc. and BioNTech SE announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy analysis conducted on November 8, 2020 ...
Regulatory Approval From Paul-Ehrlich-Institut to Commence German Part of Global Phase 2/3 Trial Received
BioNTech SE and Pfizer Inc. announced that the German regulatory authority, the Paul-Ehrlich-Institut, has approved the Phase 2/3 clinical trial in Germany for their BNT162b2 vaccine candidate. The study in Germany is part of the global pivotal Phase 2/3 program BioNTech and Pfizer initiated in ...
Doses expected to be delivered in 2020 and 2021
Pfizer Inc. and BioNTech SE announced an agreement with the United Kingdom to supply 30million doses of their BNT162 mRNA-based vaccine candidate against SARS-CoV-2, currently in development, subject to clinical success and regulatory approval. Financial details of the agreement were not ...
Efforts to manufacture the leading candidates, at risk, are gearing up
Pfizer Inc. and BioNTech SE announced preliminary U.S. data from the most advanced of four investigational vaccine candidates from their BNT162 mRNA-based vaccine program, Project Lightspeed, against SARS-CoV-2, the virus causing the current global pandemic. The BNT162 program is evaluating at ...
BioNTech SE and Pfizer Inc. disclosed additional details of their collaboration to advance candidates from BioNTech’s mRNA vaccine program, previously announced on March 17, 2020. The collaboration aims to rapidly advance multiple COVID-19 vaccine candidates into human clinical testing based on ...